GlassScriptPhysician profile
Crystal M Travis
NPI 1003255266
$333,446.05
in general payments reported to CMS, 2019-2025
25 companies · $84K in 2025
The $84K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57K · 2022: $48K · 2023: $74K · 2024: $70K · 2025: $84K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Consulting Fee: $38K · Honoraria: $19K · Travel and Lodging: $19K · Food and Beverage: $14K · Education: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138,650.50 |
| Consulting Fee | $37,991.50 |
| Honoraria | $19,125.00 |
| Travel and Lodging | $18,545.02 |
| Food and Beverage | $13,823.53 |
| Education | $425.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $205,679.74 | 2021-2025 | |
| Axsome Therapeutics, INC. | $58,616.88 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $47,225.28 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $8,383.63 | 2024-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $8,138.89 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $1,107.56 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $997.22 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $709.61 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $707.32 | 2021-2022 | |
| Alkermes, INC. | $532.17 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $413.03 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $340.42 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $120.37 | 2023-2025 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.39 | 2024-2025 | Xifaxan, Trulance |
| Validus Pharmaceuticals LLC | $72.00 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $62.21 | 2023 | Perseris |
| Dexcom, INC. | $60.43 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $47.60 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $32.03 | 2024-2025 | Wegovy |
| Exact Sciences Corporation | $29.02 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $23.79 | 2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $16.31 | 2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $16.26 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $15.89 | 2024 | Airsupra |
| Pfizer INC. | $15.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.